Pain Therapeutics (NASDAQ:PTIE) shares saw strong trading volume on Wednesday . 266,612 shares changed hands during mid-day trading, an increase of 98% from the previous session’s volume of 134,503 shares.The stock last traded at $2.29 and had previously closed at $2.40.

Separately, Zacks Investment Research lowered shares of Pain Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th.

The stock’s market cap is $109.35 million. The firm has a 50 day moving average of $2.48 and a 200-day moving average of $2.24.

Pain Therapeutics (NASDAQ:PTIE) last issued its earnings results on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.07. Equities research analysts anticipate that Pain Therapeutics will post ($0.42) EPS for the current year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.